OncRef

Clinical Trial: NCT05224141

Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 3

Lead Sponsor:Merck Sharp & Dohme LLC
Information Provided By:Merck Sharp & Dohme LLC
Last Update Posted:2025-07-08

Study Overview

Brief Summary

This study will evaluate the combination of a fixed dose pembrolizumab/vibostolimab co-formulation (MK-7684A) with etoposide/platinum chemotherapy followed by MK-7684A compared to the combination of atezolizumab with etoposide/platinum chemotherapy followed by atezolizumab in the first-line treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC). The primary hypothesis is, with respect to overall survival, MK-7684A in combination with the background therapy of etoposide/platinum followed by MK-7684A, is superior to atezolizumab in combination with the background therapy of etoposide/platinum followed by atezolizumab.

Official Title

A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination With Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination With Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer (KEYVIBE-008)

Conditions

Small Cell Lung Carcinoma

Intervention / Treatment

  • Biological: Pembrolizumab/Vibostolimab Co-Formulation
  • Drug: Saline placebo
  • Drug: Etoposide
  • Drug: Cisplatin
  • Biological: Atezolizumab
  • Drug: Carboplatin

Other Study ID Numbers

  • 7684A-008
  • MK-7684A-008
  • KEYVIBE-008
  • jRCT2021220008
  • 2023-503517-30-00
  • U1111-1287-4436
  • 2021-005034-42
  • 2023

Start Date (Actual)

2022-03-24

Primary Completion Date (Actual)

2024-06-04

Study Completion Date (Estimated)

2027-06-07

Enrollment (Actual)

460

Study Type

Interventional

Phase

Phase 3